Evidence map›Paper›PMID 40274677›Full record

ArticleDigestive diseases and sciences2025

Liver Transplantation and Metabolic Dysfunction Associated Steatotic Liver Disease Is Associated with Markers of Metabolic Risk and Inflammation.

Rehan Razzaq, Madison Nguyen, Margery A Connelly, Alok Baral, Hiba Khan, Shreya Garg, Audrey Ang, Alexis Kim, Geneva Roache, Kavish R Patidar and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rehan Razzaq *Department of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Madison Nguyen *Department of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Margery A ConnellyLabcorp, Morrisville, NC, USA.
Alok BaralDepartment of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Hiba KhanDepartment of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Shreya GargDepartment of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Audrey AngDepartment of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Alexis KimDepartment of Internal Medicine, Virginia Commonwealth University (VCU), Richmond, VA, USA.
Geneva RoacheDivision of Gastroenterology and Hepatology, VCU, MCV Campus, West Hospital, 1200 E. Broad St, PO Box 980341, Richmond, VA, 23298-0341, USA.
Kavish R PatidarBaylor University, Waco, TX, USA.
Idris YakubuDivision of Transplant Surgery, VCU, Richmond, VA, USA.
Irina ShalaurovaLabcorp, Morrisville, NC, USA.
Stephan J L BakkerDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen (UMCG), Groningen, Netherlands.
Robin P F DullaartDivision of Endocrinology, Department of Internal Medicine, University of Groningen, UMCG, Groningen, Netherlands.
Vinay KumaranDivision of Transplant Surgery, VCU, Richmond, VA, USA.
Anh T BuiDepartment of Statistical Science and Operations Research, VCU, Richmond, USA.
Vaishali Patel *Division of Gastroenterology and Hepatology, VCU, MCV Campus, West Hospital, 1200 E. Broad St, PO Box 980341, Richmond, VA, 23298-0341, USA.
Mohammad Shadab Siddiqui *Division of Gastroenterology and Hepatology, VCU, MCV Campus, West Hospital, 1200 E. Broad St, PO Box 980341, Richmond, VA, 23298-0341, USA. mohammad.siddiqui@vcuhealth.org.

Funding

Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosisR01DK129564 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI ARUN J SANYAL, Mohammad Shadab Siddiqui · 2022 to 2026
$2.8M
NIDDK NIH HHS R01 DK129564NIH HHS R01 DK129564-01
6 · The paper itself

Abstract

backgroundLiver transplant (LT) recipients are at high risk of cardiometabolic disease and mortality. However, routinely employed clinical risk tools have sub-optimal diagnostic performance due to transplant related biological changes. Metabolic vulnerability index (MVX) is a serum-based composite biomarker comprised of nutritional risk [metabolic malnutrition index or MMX] and chronic inflammation [inflammatory vulnerability index or IVX]. MVX is a predictor of cardiovascular risk and all-cause mortality in the general population, however, the effect of LT on MVX is unknown.

methodsTo better quantify MVX after transplantation, LT recipients (n = 181) prospectively enrolled in a natural history study were matched with non transplant controls from the MESA study of healthy individuals. All controls were matched 1:1 regarding age and gender. Additionally, lean controls were identified as those with BMI < 25 kg/m

resultsCompared to matched controls, LT recipients had significantly higher MVX (56.9 ± 10.1 vs. 45.8 ± 9.4 vs. 44.8 ± 9.3, p < 0.001), IVX [53.1 ± 12 vs. 39.3 ± 11.2 vs. 40.2 ± 10.9, p < 0.001), and MMX (58.7 ± 8.2 vs. 55.4 ± 6.5 vs. 53.1 ± 6.0, p < 0.001). No significant differences were noted in MVX in LT recipients who developed metabolic dysfunction associated steatotic liver disease (MASLD) after LT. In a multivariate analysis, MVX scores were positively associated with female gender, diabetes, serum AST and BMI, and negatively with dyslipidemia.

conclusionLT is associated with a significant increase in MVX and its components, suggesting a heightened risk in LT recipients that is above that of the non-LT population. Future well designed prospective studies are required to calibrate MVX to clinical outcomes in LT patients.

Indexed as

Fatty LiverInflammationLiver TransplantationAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsBiomarkersFrailtyInflammationLiver transplantationMetabolic dysfunction associated steatohepatitisMetabolic vulnerability index

Identifiers

PMID40274677
PMCPMC12185572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.